ROCKVILLE, Md., June 26 /PRNewswire/ -- Pinnacle Biologics, a private, full service pharmaceutical and biotech solutions company, today announced that it has entered into a preferred stock purchase transaction with MedImmune, LLC, pursuant to which MedImmune has acquired certain unspecified number of preferred stock shares of Pinnacle Biologics, Inc. The terms of the agreement were not disclosed.
Pinnacle Biologics owns the marketing and distribution rights to MedImmune's Ethyol(R), 50 mg/ml, powder for solution for infusion in Western Europe, Turkey and Israel.
"This is a highpoint for Pinnacle, as it signifies an additional milestone for our company," said Guillermo Herrera, Chairman of the Board of Pinnacle Biologics.
About Pinnacle Biologics
Founded in 2007 by health care executives Guillermo Herrera, James Miller, and Viren Grover, Pinnacle Biologics is a premier international company that excels in assisting pharmaceutical and biotech companies that require a total solution in either launching products or maximizing/monetizing the value of products late in their life cycle. Pinnacle forms exclusive relationships with research-based pharmaceutical multi-national corporations and biotechnology companies to take products to the next level.
Pinnacle provides a full range of services including regulatory, sales,
marketing, distribution (including billing and collections),
pharmacovigilence, product safety, market research and administrative
James R. Miller, Pinnacle
President & CEO
1 (240) 372-4599
|SOURCE Pinnacle Biologics|
Copyright©2008 PR Newswire.
All rights reserved